Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

被引：0
|
作者：
Pauline Corbaux
Audrey Lardy-Cleaud
Marie Alexandre
Maxime Fontanilles
Christelle Lévy
Alessandro Adriano Viansone
Audrey Mailliez
Marc Debled
Anthony Goncalves
Fanny Le Du
Florence Lerebours
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Thierry Petit
Jean-Sébastien Frenel
Florence Dalenc
Coralie Courtinard
Marie Chaix
Thomas Bachelot
机构：
[1] Centre Léon Bérard,Department of Medical Oncology
[2] Centre Léon Bérard,Biostatistics Unit, DRCI
[3] Institut Régional du Cancer de Montpellier,Department of Medical Oncology
[4] Centre Henri Becquerel,Department of Medical Oncology
[5] Centre François Baclesse,Department of Medical Oncology
[6] Institut Gustave Roussy,Department of Cancer Medicine
[7] Centre Oscar Lambret,Department of Medical Oncology
[8] Institut Bergonié,Department of Medical Oncology
[9] Institut Paoli-Calmettes,Department of Medical Oncology
[10] Centre Eugène Marquis,Department of Medical Oncology
[11] Institut Curie,Department of Medical Oncology
[12] Centre Antoine Lacassagne,Department of Medical Oncology
[13] Institut Jean Godinot,Department of Medical Oncology
[14] Centre Jean Perrin,Department of Medical Oncology
[15] Centre Paul Strauss,Department of Medical Oncology
[16] Institut de Cancérologie de l’Ouest René Gauducheau,Department of Medical Oncology
[17] Institut Claudius Regaud—IUCT Oncopole,Department of Medical Oncology
[18] Unicancer,Data Office
[19] Université de Bordeaux,Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219
[20] Centre Hospitalier Universitaire Dijon Bourgogne,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
Advanced breast cancer; HR+/HER2−; Endocrine therapy; Chemotherapy; Progression-free survival; Real-word data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 207
页数：16
相关论文
共 50 条
  • [21] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [22] The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
    Aranda-Gutierrez, Alejandro
    Meraz-Brenez, Andres
    Gonzalez-Sanchez, Hector Raul
    Verduzco-Aguirre, Haydee Cristina
    Martinez-Cannon, Bertha Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Yayoi Adachi
    Isao Oze
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Haruru Kotani
    Ayumi Kataoka
    Kayoko Sugino
    Nanae Horisawa
    Yuri Ozaki
    Yuka Endo
    Kazuki Nozawa
    Daiki Takatsuka
    Hiroji Iwata
    Breast Cancer, 2021, 28 : 1087 - 1095
  • [24] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Adachi, Yayoi
    Oze, Isao
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kotani, Haruru
    Kataoka, Ayumi
    Sugino, Kayoko
    Horisawa, Nanae
    Ozaki, Yuri
    Endo, Yuka
    Nozawa, Kazuki
    Takatsuka, Daiki
    Iwata, Hiroji
    BREAST CANCER, 2021, 28 (05) : 1087 - 1095
  • [25] Association of endocrine therapy with overall survival in women with hormone receptor-positive, HER2-negative, node-negative breast cancer of favorable histology
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    Ma, Sung Jun
    BREAST JOURNAL, 2020, 26 (10): : 2006 - 2010
  • [26] Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer
    Maurer, Christian
    Ferreira, Arlindo R.
    Martel, Samuel
    Lambertini, Matteo
    Ponde, Noam
    Aftimos, Philippe
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2018, 39 : 14 - 18
  • [27] Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy
    O'Reilly, David
    Farooq, Abdul Rehman
    Selvadurai, Paul Nevins
    Sheehan, Laura
    Molan, Karen
    Krishnanivas, Bindu
    Mullen, Valerie
    Mcmahon, David
    Hadi, Danial
    Ahmed, Ahmed
    Jennings, Maeve
    Carroll, Hailey
    Chew, Sonya
    Macanovic, Bojan
    Brown, Ciara O'Hanlon
    Noonan, Sinead A.
    Reilly, Seamus O.
    Connolly, Roisin M.
    Cahir, Caitriona
    Kelly, Catherine M.
    ONCOLOGIST, 2024, 29 (10): : 842 - 849
  • [28] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
  • [29] Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
    Malorni, L.
    Curigliano, G.
    Minisini, A. M.
    Cinieri, S.
    Tondini, C. A.
    D'Hollander, K.
    Arpino, G.
    Bernardo, A.
    Martignetti, A.
    Criscitiello, C.
    Puglisi, F.
    Pestrin, M.
    Sanna, C.
    Moretti, E.
    Risi, E.
    Biagioni, C.
    McCartney, A.
    Boni, L.
    Buyse, M.
    Migliaccio, I.
    Biganzoli, L.
    Di Leo, A.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1748 - 1754
  • [30] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
12345